Taken together, these results suggest that AKT1 is a crucial regulator of STING signaling in endocrine‐resistant breast cancer cells and that knockdown of AKT1 or targeting AKT1 by MK2206 could release the activity of STING signaling. Here, AKT1 is linked to breast cancer.